BPG is committed to discovery and dissemination of knowledge
Articles in Press
12/19/2025 12:12:36 PM | Browse: 21 | Download: 0
| Category |
Oncology |
| Manuscript Type |
Editorial |
| Article Title |
Inflammatory cytokine-associated cisplatin resistance in non-small cell lung cancer and re-sensitization through interleukin-6 receptor blockade
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Gizem Calibasi-Kocal |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Gizem Calibasi-Kocal, Department of Translational Oncology, Institute of Oncology, Dokuz Eylul University, Cumhuriyet Bulvarı 144, Alsancak, Izmir 35330, Türkiye. gizem.calibasi@deu.edu.tr |
| Key Words |
Non-small cell lung cancer; Cisplatin resistance; Cytokines; Interleukin -6; Tumor microenvironment |
| Core Tip |
Dai et al’s research study explores the association between inflammatory cytokines and cisplatin (DDP) resistance in non-small cell lung cancer (NSCLC). Elevated levels of interleukin (IL)-6 and IL-8 were identified as key risk factors contributing to cisplatin resistance in NSCLC. Notably, IL-6 inhibition via the receptor antagonist tocilizumab restored DDP sensitivity and attenuated malignant phenotypes in resistant cell lines, by reducing cell viability, migration, and invasion, while enhancing apoptosis. These findings highlight the tumor microenvironment-cytokine interplay, particularly IL-6 signaling, as a critical determinant and potential therapeutic avenue in overcoming DDP resistance in NSCLC. |
| Citation |
Calibasi-Kocal G. Inflammatory cytokine-associated cisplatin resistance in non-small cell lung cancer and re-sensitization through interleukin-6 receptor blockade. World J Clin Oncol 2025; In press |
 |
Received |
|
2025-09-15 00:50 |
 |
Peer-Review Started |
|
2025-09-15 00:50 |
 |
First Decision by Editorial Office Director |
|
2025-09-22 09:17 |
 |
Return for Revision |
|
2025-09-22 09:17 |
 |
Revised |
|
2025-10-06 01:08 |
 |
Publication Fee Transferred |
|
|
 |
Second Decision by Editor |
|
2025-12-19 02:37 |
 |
Second Decision by Editor-in-Chief |
|
|
 |
Final Decision by Editorial Office Director |
|
2025-12-19 12:12 |
 |
Articles in Press |
|
2025-12-19 12:12 |
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
|
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345